Ten years later, Lilly's long-term Alzheimer's trial of solanezumab has definitively failed
A trial of Eli Lilly’s Alzheimer’s drug solanezumab that began in 2013 didn’t show any benefit in patients, who were followed for a decade to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
